Verastem Inc (VSTM)

Jun 2, 2025, 9:40 AM EDT - 7 days ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 12 days ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 18 days ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 8:30 AM EDT - 20 days ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 27 days ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 4 weeks ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 4 weeks ago

U.S. FDA approves Verastem's cancer therapy

May 1, 2025, 7:30 AM EDT - 5 weeks ago

Verastem Oncology to Present at Upcoming Investor Conferences

Apr 25, 2025, 9:00 AM EDT - 6 weeks ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 6 weeks ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 10, 2025, 2:35 PM EDT - 2 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Apr 7, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2025, 4:35 PM EDT - 2 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 2 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 3 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 7:30 AM EST - 4 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 4 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 5 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 5 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 5 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 3, 2025, 11:56 AM EST - 5 months ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 5 months ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Dec 31, 2024, 10:59 AM EST - 5 months ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 30, 2024, 4:30 PM EST - 5 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 6 months ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Nov 27, 2024, 1:28 PM EST - 6 months ago

Verastem: Preparing For Upcoming Catalysts

Nov 26, 2024, 7:00 AM EST - 6 months ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 4:05 PM EST - 7 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 7 months ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 7:30 AM EDT - 7 months ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 17, 2024, 1:00 AM EDT - 8 months ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 8 months ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Sep 10, 2024, 4:05 PM EDT - 9 months ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:30 AM EDT - 9 months ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Sep 5, 2024, 11:21 PM EDT - 9 months ago

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Sep 3, 2024, 7:30 AM EDT - 9 months ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Aug 8, 2024, 4:05 PM EDT - 10 months ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Jul 29, 2024, 4:01 PM EDT - 11 months ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Jul 23, 2024, 11:20 PM EDT - 11 months ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 23, 2024, 4:05 PM EDT - 11 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 12, 2024, 7:30 AM EDT - 11 months ago

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

Jul 10, 2024, 2:48 PM EDT - 11 months ago

Verastem, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 1, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes

Jun 10, 2024, 10:51 AM EDT - 1 year ago

Verastem: Market Overreaction Creates A Dip Buying Opportunity